MANUS BIO INC
WALTHAM, MA · CIK 0001686230 · Biotech · Private
Bioengineered molecules and chemicals produced through fermentation to replace petrochemical and agricultural-sourced ingredients
manusbio.com →- Grants
- $99K
- 1 award
- Sector median: 1
- Raised
- $109M
- 6 Form D · May 2024
- 29 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 17 granted · 23 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201620172018201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $300,000 | |
| Private capital raised | Form D · SEC | $7,022,700 | |
| Private capital raised | Form D · SEC | $10,000,000 | |
| Federal grant | Department of Agriculture · Combined Fermentation-based Biosynthesis And Whole-animal Screening Platform For Biobased Nematicide Discovery & Commercialization | $98,980 | |
| Private capital raised | Form D · SEC | $66,187,702 | |
| Private capital raised | Form D · SEC | $21,225,000 | |
| Private capital raised | Form D · SEC | $11,270,003 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2377 | DNP THERAPEUTICS INC | — | $470K |
| 2378 | XFIBRA, INC. | — | — |
| 2379 | ISIS PHARMACEUTICALS INC | — | $201M |
| 2380 | MANUS BIO INC | — | $109M |
| 2381 | Jaguar Health, Inc. | — | $146M |
| 2382 | MediWound Ltd. | — | $31M |
| 2383 | SALIX PHARMACEUTICALS LTD | — | $750M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Bryon AlsbergDirector
- Byron AlsbergDirector
- Jeff AndersonExecutive Officer
- Carsten BoersDirector
- Paul BoniExecutive Officer
- Michael CarlosDirector
- Raymond ChangDirector
- Rick GersonDirector
- Richard GoldsteinDirector
- Colin GoundenDirector
- Jeremiah HuxExecutive Officer
- Alena IvashenkaDirector
- Ajikumar KumaranDirector · Executive Officer
- Zanna McFersonDirector
- Jean NehmeDirector
- John NehmeDirector
- Ajikumar ParayilDirector · Executive Officer
- Julio Ruiz CalderonExecutive Officer
- Christine SantosExecutive Officer
- Gregory StephanopoulosDirector
- Jason WhaleyDirector
Patents
- Glycoside Product Biosynthesis And Recoveryapplication
- Enzymes, Cells, And Methods For Producing Lactonesapplication
- Microbial Production Of Mogrol And Mogrosidesapplication
- Microbial Production Of Triterpenoids Including Mogrosidesapplication
- Methods For Production Of Oxygenated Terpenesapplication
- Methods For Production Of Oxygenated Terpenesgranted
- Microbial Production Of Mogrol And Mogrosidesgranted
- Uridine Diphosphate-dependent Glycosyltransferase Enzymegranted
- Enzymes, Cells, And Methods For Producing CIS-3 Hexenolapplication
- Fermentation Processes And Systemsapplication
- Microbial Production Of Triterpenoids Including Mogrosidesgranted
- Compositions Comprising Milk Fat Triglycerides Produced By Microbial Fermentationapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.